Kremyanskaya Highlights the Benefits of BET Inhibitors in Myelofibrosis

Season 9 Episode 7  ·  Jul 03, 2023, 06:00 PM

Headliner
Share
Subscribe

Dr Kremyanskaya discusses the results from cohort 1 of the MANIFEST trial in treatment-naïve myelofibrosis, differentiating features of pelabresib and recently approved JAK inhibitors, and next steps for the investigation of BET inhibitors in this population.

Share
Subscribe
Next
King Describes Unmet Needs and the Role of Surgical Resection in Residual Non-RP Testicular Cancer
Top episodes
DeNunzio Describes the Advantages of Proton Beam Therapy in Oncology
by OncLive® On Air
FDA Approval Insights: Amivantamab and Mobocertinib in EGFR Exon 20 Insertion+ NSCLC
by OncLive® On Air
Milhem Talks Mechanism of Action, Delivery Methodology, and Ongoing Trials With RP1
by OncLive® On Air